The NEPIC Directory > Fujifilm Diosynth Biotechnologies


Fujifilm Diosynth Biotechnologies

FUJIFILM Diosynth Biotechnologies is an industry leading biologics contract manufacturing organisation with locations in Billingham and Wilton, United Kingdom, Research Triangle Park, NC, USA and College Station, TX USA. FUJIFILM Diosynth Biotechnologies has extensive experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules expressed in a wide array of microbial mammalian and insect systems. The company offers a comprehensive list of services from cell line and strain development to process development, analytical development, clinical and commercial manufacturing. The Billingham and RTP sites are FDA-approved for the production of commercial products.


Latest Posts

Fujifilm announces a further £614m investment in bio manufacturing

Fujifilm Diosynth Biotechnologies

Credit: Tees Business Global biologics company Fujifilm Diosynth Biotechnologies has announced a multi-million-pound investment to “significantly increase” its manufacturing capabilities. The Texas-based firm already employs 850 people at its Billingham site, where it’s producing 60 million doses of the Novavax…

Read more >

Profits up at COVID-19 Vaccine maker

Fujifilm Diosynth Biotechnologies

Pre-tax profits have increased slightly at the Billingham-headquartered UK arm of a cell culture, microbial fermentation and gene therapy specialist, newly filed accounts have revealed. FUJIFILM Diosynth Biotechnologies supports customers with the development and production of recombinant proteins, viral vaccines…

Read more >

Covid vaccine to be made on Teesside after tests show 90% effectiveness

Fujifilm Diosynth Biotechnologies

The UK has secured 60 million doses of the Novavax vaccine which will be made in Billingham. The development of a covid-19 vaccine to be made on Teesside has taken a huge step forward after tests showed it is largely…

Read more >

Fujifilm to Invest Over 2 Billion USD to Establish New Large-Scale Cell Culture Manufacturing Site for Biopharmaceuticals

Fujifilm Diosynth Biotechnologies

FUJIFILM Corporation is making an investment of more than 200 Billion yen (2 Billion USD) to establish a new large-scale cell culture production site in the United States to accelerate the growth of its biopharmaceutical contract development and manufacturing business…

Read more >

Non-Executive Chairman Of FUJIFILM Diosynth Biotechnologies Recognised In New Year’s Honours List 2021

Fujifilm Diosynth Biotechnologies

FUJIFILM Diosynth Biotechnologies, is pleased to share that Steve Bagshaw, non-executive chairman of FUJIFILM Diosynth Biotechnologies, has been awarded Commander of the Most Excellent Order of the British Empire (CBE) for Services to the U.K. Manufacturing and Biotechnology Sector in…

Read more >

Teesside-based gene therapy firm expands

Fujifilm Diosynth Biotechnologies

A Biotechnology firm is set to expand its operations at its Teesside site. Tees Valley Mayor Ben Houchen has welcomed the news that FUJIFILM Diosynth Biotechnologies is expanding its operations in Billingham with additional state-of-the-art laboratories. The news laboratories will…

Read more >

Share this

Not a Member? Member Login

Company Contact Details

-

http://www.fujifilmdiosynth.com

+44 (0) 1642 363 511

Belasis Avenue, Billingham, Stockton-on-Tees, TS23 1LH


© Copyright. North East of England Process Industry Cluster (NEPIC) 2015

Built by iTCHYROBOTiTCHYROBOT Logo